HomeCompareABBV vs BKR

ABBV vs BKR: Dividend Comparison 2026

ABBV yields 3.12% · BKR yields 1.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.3K in total portfolio value
10 years
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →
BKR
BKR
● Live price
1.52%
Share price
$60.68
Annual div
$0.92
5Y div CAGR
27.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.4K
Annual income
$2,429.16
Full BKR calculator →

Portfolio growth — ABBV vs BKR

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVBKR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + BKR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
BKR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
BKR
Annual income on $10K today (after 15% tax)
$128.87/yr
After 10yr DRIP, annual income (after tax)
$2,064.79/yr
At 15% tax rate, ABBV beats the other by $19,802.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + BKR for your $10,000?

ABBV: 50%BKR: 50%
100% BKR50/50100% ABBV
Portfolio after 10yr
$67.6K
Annual income
$14,077.44/yr
Blended yield
20.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BKR right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
BKR
Analyst Ratings
31
Buy
13
Hold
1
Sell
Consensus: Buy
Price Target
$60.80
+0.2% upside vs current
Range: $52.00 — $68.00
Altman Z
2.6
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
0
BKR buys
0
No recent congressional trades found for ABBV or BKR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVBKR
Forward yield3.12%1.52%
Annual dividend / share$6.65$0.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%27.4%
Portfolio after 10y$104.7K$30.4K
Annual income after 10y$25,725.73$2,429.16
Total dividends collected$63.0K$9.0K
Payment frequencyquarterlyquarterly
SectorHealthcareEnergy
Analyst consensusBuyBuy
Analyst price target$256.15$60.80

Year-by-year: ABBV vs BKR ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrBKR PortfolioBKR Income/yrGap
1← crossover$11,559$438.51$10,893$193.16+$666.00ABBV
2$13,494$640.86$11,906$250.53+$1.6KABBV
3$15,951$945.97$13,066$326.03+$2.9KABBV
4$19,152$1,413.89$14,406$425.99+$4.7KABBV
5$23,443$2,146.38$15,974$559.25+$7.5KABBV
6$29,391$3,321.96$17,830$738.33+$11.6KABBV
7$37,948$5,265.87$20,060$981.27+$17.9KABBV
8$50,795$8,596.74$22,778$1,314.43+$28.0KABBV
9$71,034$14,549.41$26,150$1,777.14+$44.9KABBV
10$104,715$25,725.73$30,410$2,429.16+$74.3KABBV

ABBV vs BKR: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

BKREnergy

Baker Hughes Company provides a portfolio of technologies and services to energy and industrial value chain worldwide. It operates through four segments: Oilfield Services (OFS), Oilfield Equipment (OFE), Turbomachinery & Process Solutions (TPS), and Digital Solutions (DS). The OFS segment offers exploration, drilling, wireline, evaluation, completion, production, and intervention services; and drilling and completions fluids, wireline services, downhole completion tools and systems, wellbore intervention tools and services, pressure pumping systems, oilfield and industrial chemicals, and artificial lift technologies for oil and natural gas, and oilfield service companies. The OFE segment provides subsea and surface wellheads, pressure control and production systems and services, flexible pipe systems for offshore and onshore applications, and life-of-field solutions, including well intervention and decommissioning solutions; and services related to onshore and offshore drilling and production operations. The TPS segment provides equipment and related services for mechanical-drive, compression, and power-generation applications across the oil and gas industry. Its product portfolio includes drivers, compressors, and turnkey solutions; and pumps, valves, and compressed natural gas and small-scale liquefied natural gas solutions. This segment serves upstream, midstream, downstream, onshore, offshore, and industrial customers. The DS segment provides sensor-based process measurements, machine health and condition monitoring, asset strategy and management, control systems, as well as non-destructive testing and inspection, and pipeline integrity solutions. The company was formerly known as Baker Hughes, a GE company and changed its name to Baker Hughes Company in October 2019. Baker Hughes Company is based in Houston, Texas.

Full BKR Calculator →
📬

Get this ABBV vs BKR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.